Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Domenico Alvaro

Showing results (201-210 of 215) with videos related to

Pageof 22
Sort By:
United European Gastroenterology Journal|June 20, 2020
European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendationsJ-Matthias Löhr, Ulrich Beuers, Miroslav Vujasinovic, et al.
Journal of Clinical Medicine|July 13, 2024
Final Results from the First European Real-World Experience on Lusutrombopag Treatment in Cirrhotic Patients with Severe Thrombocytopenia: Insights from the REAl-World Lusutrombopag Treatment in ITalY StudyPaolo Gallo, Antonio De Vincentis, Francesca Terracciani, et al.
Nature Reviews. Gastroenterology & Hepatology|July 2, 2020
Cholangiocarcinoma 2020: the next horizon in mechanisms and managementJesus M Banales, Jose J G Marin, Angela Lamarca, et al.
Nature Reviews. Gastroenterology & Hepatology|February 9, 2023
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevanceDiego F Calvisi, Luke Boulter, Javier Vaquero, et al.
Hepatology (Baltimore, Md.)|June 13, 2025
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries' framework for digital twin advancementGuido Carpino, Diletta Overi, Rocio Ir Macias, et al.
The Lancet. Gastroenterology & Hepatology|July 19, 2018
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response ScoreMarco Carbone, Alessandra Nardi, Steve Flack, et al.
Journal of Hepatology|February 15, 2022
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA RegistryLaura Izquierdo-Sanchez, Angela Lamarca, Adelaida La Casta, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2024
Noninvasive Assessment of portal Hypertension in Patients With Primary Biliary Cholangitis is Affected by Severity of CholestasisVincenza Calvaruso, Ciro Celsa, Laura Cristoferi, et al.
JHEP Reports : Innovation in Hepatology|March 8, 2021
Real-world experience with obeticholic acid in patients with primary biliary cholangitisDaphne D'Amato, Antonio De Vincentis, Federica Malinverno, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 6, 2022
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acidAntonio De Vincentis, Daphne D'Amato, Laura Cristoferi, et al.
Pageof 22

Showing results (201-210 of 215) with videos related to

Sort By:
Pageof 22
United European Gastroenterology Journal|June 20, 2020
European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendationsJ-Matthias Löhr, Ulrich Beuers, Miroslav Vujasinovic, et al.
Journal of Clinical Medicine|July 13, 2024
Final Results from the First European Real-World Experience on Lusutrombopag Treatment in Cirrhotic Patients with Severe Thrombocytopenia: Insights from the REAl-World Lusutrombopag Treatment in ITalY StudyPaolo Gallo, Antonio De Vincentis, Francesca Terracciani, et al.
Nature Reviews. Gastroenterology & Hepatology|July 2, 2020
Cholangiocarcinoma 2020: the next horizon in mechanisms and managementJesus M Banales, Jose J G Marin, Angela Lamarca, et al.
Nature Reviews. Gastroenterology & Hepatology|February 9, 2023
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevanceDiego F Calvisi, Luke Boulter, Javier Vaquero, et al.
Hepatology (Baltimore, Md.)|June 13, 2025
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries' framework for digital twin advancementGuido Carpino, Diletta Overi, Rocio Ir Macias, et al.
The Lancet. Gastroenterology & Hepatology|July 19, 2018
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response ScoreMarco Carbone, Alessandra Nardi, Steve Flack, et al.
Journal of Hepatology|February 15, 2022
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA RegistryLaura Izquierdo-Sanchez, Angela Lamarca, Adelaida La Casta, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2024
Noninvasive Assessment of portal Hypertension in Patients With Primary Biliary Cholangitis is Affected by Severity of CholestasisVincenza Calvaruso, Ciro Celsa, Laura Cristoferi, et al.
JHEP Reports : Innovation in Hepatology|March 8, 2021
Real-world experience with obeticholic acid in patients with primary biliary cholangitisDaphne D'Amato, Antonio De Vincentis, Federica Malinverno, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 6, 2022
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acidAntonio De Vincentis, Daphne D'Amato, Laura Cristoferi, et al.
Pageof 22